In vitro activation of Irinotecan to SN-38 by human liver and intestine

Anticancer Research

Volumn 19, Issue 3 A, 1999, Pages 2067-2071

  Ahmed, Farheena ^a   Vyas, Viral ^a   Cornfield, Adam ^a   Goodin, Susan ^a   Ravikumar, T S ^a   Rubin, Eric H ^a   Gupta, Elora ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Carboxylesterase; Intestine; Liver; Metabolism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; IRINOTECAN;

ARTICLE; COLON; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG ACTIVATION; DRUG HYDROLYSIS; DRUG METABOLISM; DUODENUM; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE; INTESTINE MUCOSA; JEJUNUM; LIVER; PRIORITY JOURNAL; RECTUM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; COLON; DUODENUM; HUMANS; HYDROLYSIS; ILEUM; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; INTESTINES; JEJUNUM; LIVER NEOPLASMS; MICROSOMES; MICROSOMES, LIVER; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PRODRUGS; RECTUM;

EID: 0032791202     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rivory LP, Bowles MR, Robert J and Pond SM: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111, 1996.
2. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T and Tsuru D: CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobio-Dyn 14: 341-349, 1991.
3. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
4. Dodds HM, Haaz M-C, Riou J-F, Robert J and Rivory LP: Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286: 578-583, 1998.
5. Nagai S, Yamauchi M, Andoh T, Nishizawa M, Satta T, Kodera Y, Kondou K, Akiyama S, Ito K and Takagi H: Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J Surg Oncol 59: 116-124, 1995.
6. Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y and Saijo N: Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52: 328-333, 1992.
7. Ogasawara H, Nishio K, Kanzawa F, Lee YS, Funayama Y, Ohira T, Kuraishi Y, Isogai Y and Saijo N: Intracellular carboxylesterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 86: 124-129, 1995.
8. Burke TG, Munshi CB, Mi Z and Jiang Y: The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84: 518-519, 1995.
9. Atsumi R, Okazaki O and Hakusui H: Pharmacokinetics of SN-38 [(+)-(4S)-4, 11,-diethyl-4, 9-dihydroxy-1 H-pyrano[3',4':6,7]-indolino [1, 2-b]quinoline-3, 14(4H, 12H)- dione], an active metabolite of irinotecan, after a single intravenous dosing of [14C]- SN-38 to rats. Biol Pharm Bull 18: 114-119, 1995.
10. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE and Ratain MJ: Pharmacokinetics and pharmacodynamic evaluation of topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15: 1502-1510, 1997.
11. Drengler R, Burris H, Dietz A, Eckardt J, Eckhardt G, Hodges S, Kraynak M, Kuhn J, Peacock N, Rinaldi D, Rizzo J, Rodriguez G, Schaaf L, Smith L, Thurman A and Von Hoff D: A phase I trial to evaluate orally administbred irinotecan HCL (CPT-11) given daily X 5 every three weeks in patients with refractory malignancies. Proc Am Assoc Clin Oncol 15: 489, 1996
12. Araki E, Ishikawa M, ligo M, Koide T, Itabashi M and Hoshi A: Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84: 697-702, 1193.
13. Ikuno N, Soda H, Watanabe M and Oka M: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87: 1876-1883, 1995.
14. Krishna DR and Klotz U: Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26: 144-160, 1994.
15. Lund-Pero M, Jeppson B, Arneklo-Nobin B, Sjogren H-O, Holmgren K and Pero RW: Non-specific steroidal esterase activity and distribution in human and other mammalian tissues. Clin Chim Acta 224: 9-20, 1994.
16. Yamazaki H, Inoue K, Turvy CG, Guengerich FP and Shimada T: Effects of freezing, thawing and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Disp 25: 168-174, 1997.
17. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
18. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H and Nagai E: Metabolic activation of CPT-1, 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy camptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17: 662-664, 1994.
19. Slatter JG, Su P, Sams JP, Schaaf LJ and Wienkers LC: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Disp 25: 1157-1164, 1998.
20. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE and Ratain MJ: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725, 1994.
21. Schwer H, Langmann T, Daig R, Becker A, Aslanidis C and Schmitz G: Molecular cloning and characterization of a novel putative carboxylesterase present in human intestine and liver. Biochem Biophys Res Commun 233: 117-120, 1997.
22. Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X and Stewart CF: Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 4: 455462, 1998.
23. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y and Satoh T: Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Disp 23: 1022-1027, 1995
24. Lund-Pero M, Jeppson B and Pero RW: Reduced nonspecific steroidal esterase activity in human malignant tumor tissue from liver, colon and breast when compared to peritumoral and normal tissue levels. Anticancer Res 14: 2747-2753, 1994.